Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + telisotuzumab vedotin
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Combination therapy of telisotuzumab vedotin (Teliso-V), an antibody-drug conjugate targeting c-Met, with erlotinib, an EGFR tyrosine kinase inhibitor. This combination is designed to target both c-Met protein expression and EGFR mutations in non-small cell lung cancer (NSCLC). Telisotuzumab vedotin consists of a humanized monoclonal antibody against c-Met linked to monomethyl auristatin E (MMAE), a microtubule inhibitor, via a cleavable valine-citrulline peptide linker.
- Brand names
- Teliso-V + Tarceva
- Other names
- Teliso-V + Erlotinib
02
Targets
EGFR (Epidermal growth factor receptor)TUBB (Tubulin (alpha and beta subunits))MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on erlotinib + telisotuzumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + telisotuzumab vedotin.